Lyell Immunopharma (NASDAQ:LYEL – Get Free Report)‘s stock had its “buy” rating restated by research analysts at Needham & Company LLC in a report issued on Monday,Benzinga reports. They currently have a $44.00 price target on the stock. Needham & Company LLC’s price target would indicate a potential upside of 225.93% from the stock’s previous close.
A number of other analysts have also commented on LYEL. Citigroup reissued a “market outperform” rating on shares of Lyell Immunopharma in a report on Tuesday, June 9th. HC Wainwright reaffirmed a “buy” rating and set a $45.00 target price on shares of Lyell Immunopharma in a research report on Tuesday, June 9th. Citizens Jmp assumed coverage on Lyell Immunopharma in a report on Monday, March 9th. They set a “market outperform” rating and a $34.00 price target for the company. Zacks Research raised Lyell Immunopharma from a “strong sell” rating to a “hold” rating in a research report on Monday, May 18th. Finally, Robert W. Baird set a $49.00 price objective on Lyell Immunopharma and gave the company an “outperform” rating in a research note on Thursday, April 30th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Lyell Immunopharma has a consensus rating of “Moderate Buy” and a consensus price target of $43.00.
View Our Latest Stock Report on Lyell Immunopharma
Lyell Immunopharma Price Performance
Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) last posted its earnings results on Wednesday, May 6th. The company reported ($1.10) EPS for the quarter, hitting the consensus estimate of ($1.10). Lyell Immunopharma had a negative net margin of 794,858.12% and a negative return on equity of 85.71%. The company had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.00 million. As a group, equities research analysts anticipate that Lyell Immunopharma will post -7.87 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Lyell Immunopharma
A number of hedge funds and other institutional investors have recently modified their holdings of LYEL. Foresite Capital Management V LLC lifted its holdings in Lyell Immunopharma by 17.3% during the third quarter. Foresite Capital Management V LLC now owns 477,078 shares of the company’s stock worth $7,748,000 after acquiring an additional 70,426 shares during the period. Takeda Pharmaceutical Co. Ltd. boosted its position in Lyell Immunopharma by 33.3% in the third quarter. Takeda Pharmaceutical Co. Ltd. now owns 54,887 shares of the company’s stock worth $891,000 after purchasing an additional 13,722 shares during the last quarter. ExodusPoint Capital Management LP bought a new position in Lyell Immunopharma in the 4th quarter valued at $262,000. Walleye Capital LLC purchased a new stake in shares of Lyell Immunopharma during the 2nd quarter valued at $258,000. Finally, Bridgeway Capital Management LLC purchased a new stake in shares of Lyell Immunopharma during the 2nd quarter valued at $159,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.
Lyell Immunopharma Company Profile
Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.
The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.
Featured Stories
- Five stocks we like better than Lyell Immunopharma
- Qualcomm Drops 25%, But Investor Day Could Reverse the Slide
- Meta to Follow Alphabet’s Footsteps? What an Equity Raise Could Mean
- 3 ETFs Giving Ready-Made Access to the Discounted International Small-Cap Space
- What to Expect From Q2 Earnings as Tech Strength Broadens
Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.
